A few years ago, Victoria Bayle was driving with her daughter through small-town Edinboro, Pa., when suddenly her memory blanked. None of the buildings — ones she’d lived close to, along roads she’d driven for years — looked familiar. She did not know where she was going.

Idling at a stop sign, she asked her daughter, Sydney, where they were.

“You’re taking me to the eye doctor,” said Sydney, who was 16 at the time.

“And how do I get there?” Vickie Bayle replied.

Advertise with us

Only 46 at the time, Bayle, after months of tests and scans, was diagnosed with Alzheimer’s disease. She knows of no family history of Alzheimer’s, she said, and that her family “actually has super-longevity on both sides.”

Alzheimer’s Disease affects 6.5 million Americans and nearly 50 million people worldwide, and those numbers are increasing. In 2019 there were 5.8 million people with Alzheimer’s in the U.S., which means nearly one million were diagnosed just in the past two years.

And while the disease mainly affects people over 65, some 200,000 people under 65 had Alzheimer’s in 2022. Including Bayle.

Her memory lapses have happened multiple times, such as when she was at her annual Thanksgiving gathering, a time when her home is swarmed with 20 hungry people. While preparing for the meal on one occasion, she couldn’t find utensils in the house she had lived in for years.

She said these lapses were temporary, but frightening. Another she encountered while driving “only lasted a few moments, but it was unsettling, to say the least.”

Advertise with us

A handful of drugs exist to treat the condition, two of which Bayle takes. The Food and Drug Administration on Friday approved a new Alzheimer’s drug, lecanemab, developed by Eisai and Biogen. In an 18-month clinical trial of 1,795 patients, the drug slowed cognitive decline and reduced the burden of a marker of Alzheimer’s called amyloid beta, a protein in the brain that clumps together to form plaques, impairing communication between neurons.

But the study only tested people ages 50 to 90, so Bayle worries she will not qualify. Even if she does, an average of 12.6% of participants had serious adverse effects from the medication, such as dangerous brain bleeds. Bayle said she’s not sure the benefits outweigh the risks right now.

“Do I want to take the chance of not feeling well, or of something happening?” she asks. “I would rather stay feeling great.”

Biogen is under scrutiny concerning another of its Alzheimer’s drugs, Aduhelm. A House investigation released in late December reported that the pharmaceutical company and the FDA collaborated, and the FDA approved the drug three months after clinical trials for it were canceled. When Bayle inquired about Aduhelm to her doctor, she was told, “I do not back this drug.”

Victoria Bayle and her husband Charlie visit The Wizarding World of Harry Potter at Universal Studios in Orlando, Florida. (Courtesy of Victoria Bayle)

A new approach

Advertise with us

Researchers at the University of Pittsburgh and the University of Gothenburg in Sweden, along with other institutions, are taking a different approach to Alzheimer’s treatment, one that’s centered around early detection of the disease. The results of their new study, published on Dec. 27 in the journal Brain, show promise.

The team discovered that a protein in the body called tau, derived from the brain, could be detected in the blood plasma of Alzheimer’s patients. This means there is potential for doctors to eventually diagnose Alzheimer’s using a blood test, instead of the more expensive and involved route of imaging.

Tau has been used to detect Alzheimer’s, in addition to the amyloid plaques. In a person without cognitive impairment, this group of proteins helps our cells maintain their skeleton and structure. In Alzheimer’s patients, the tau proteins tangle up and can cause cells to die.

“Imaging studies are good for diagnosis,” said Dr. Thomas Karikari, associate professor of psychiatry at Pitt, with a joint appointment in Sweden, but an MRI can cost thousands of dollars, and patients can be put on months-long waitlists to receive them.

Dr. Thomas Karikari, associate professor of psychiatry at Pitt. (courtesy of Thomas Karikari)

Karikari and his team’s blood test method would help make Alzheimer’s diagnosis easier, and allow doctors to catch it earlier than an MRI might — and maybe before the brain has been as damaged. “We want to look at the early stages” of the disease, he said.

Advertise with us

The range for acceptable levels of total tau on Bayle’s results far surpassed what the literature lists as within range of normal cognition. When her doctor, who happened to be her next-door neighbor and friend, came to deliver her results, Bayle said the woman was “emotionally wrecked.” She gave her a timeline of 10 years — not all of them in which Bayle expects to be present and spry.

While some people can live up to 20 years with Alzheimer’s, the average, after diagnosis, is 4 to 8 years, per the Alzheimer’s Association.

Despite her diagnosis, Bayle maintains a stubbornly positive outlook — to a degree that has at times, she noted, surprised her family. They have been traveling around the U.S. for the past few weeks, most recently in the Colorado mountains, where her children sarcastically exclaimed, “Look, there’s mom taking another picture of a leaf!”

“I don’t mourn this, because I can’t change it,” said Bayle. “Instead, my outlook has been, ‘What’s next?’ We’ve got places to see, pictures to take.” Right now, she said, she is in a great place with recall. She and her family have been sightseeing a lot, and she has remembered all of it.

Bayle called the blood test idea “fascinating,” and hoped it would make accessing care easier. “Everybody gets blood work,” she said, “and the spinal tap was not fun.” (A spinal tap was how doctors retrieved her cerebrospinal fluid, where they detected the tau).

Advertise with us

On an Alzheimer’s forum where other researchers can comment on new studies, many in the field praised Karikari’s solid results but wanted future research to specify some parameters, so they could learn more about brain-derived (BD) tau and how it links to the presence of Alzheimer’s.

“This novel work nicely highlights the potential of blood BD-tau as an Alzheimer’s-specific marker of neurodegeneration, “ wrote Michelle Meilke, a physician at Mayo Clinic. “As the authors highlight, there are several next steps needed

Next steps

Based on their study results, Karikari hopes that FDA approval comes in about two years, but he and his team are already continuing to study tau, as well creating more diverse cohorts of study participants to increase representation in clinical trials.

This includes more patients with comorbidities. “Alzheimer’s Disease does not exist in isolation,” said Karikari. Including this data would inform scientists how a certain drug interacts differently in people with, say, diabetes. And more diversity in clinical trials also means the eligibility of a drug could be expanded, because it will have been tested on more than one population.

Advertise with us

His team is currently working on a global study matching cohorts in different countries that otherwise are the same age, sex, race, etc. Participants can donate cerebral spinal fluid, imaging results and blood to allow researchers to look at how social determinants of health change health outcomes. Social determinants of health include ways our health is impacted by factors outside the doctor’s office, such as neighborhood placement, education, access to healthy food and housing, and financial status.

“If we really want to study social determinants of health,” Karikari said, “maybe we should look at access to health.”

And access does matter. Bayle said she is blessed to have great insurance that has allowed her to get the health care she needed for diagnosis and treatment.

“I was able to advocate for myself,” she said. “What about those who cannot or are afraid to?”

She hopes that progress continues toward understanding Alzheimer’s and that more medications to slow or stop cognitive decline are created. “I wish the future solutions would happen now, so I could live long enough to meet my grandchildren.”

Advertise with us

For now, Karikari and his team’s study is a start.

Hanna Webster: hwebster@post-gazette.com.